General Information
Version
1.0
Revision date
2023-11-29
Product name
Olmesartan medoxomil for system suitability
1.2.2. Uses advised against
Do not use : Ingestion, Inhalation, Dermal
Emergency telephone
+33(0)390215608
Icons in SDS
Company Information
company name
EDQM
e-mail address of the competent person responsible for the Safety Data Sheet
sds@edqm.eu
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H360, H373
Hazard statements
Code
Statements
H360
May damage fertility or the unborn child
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
Expert judgement and weight of evidence determination.
2.2 Label elements
Labelling
Hazard pictograms
GHS08 GHS08
Signal word
Danger
Contains
Olmesartan medoxomil
Hazard statements
H360 - May damage fertility or the unborn child. H373 - May cause damage to organs through prolonged or repeated exposure.
Precautionary statements
P201 - Obtain special instructions before use. P202 - Do not handle until all safety precautions have been read and understood. P260 - Do not breathe dust/fume/gas/mist/vapours/spray. P280 - Wear protective gloves/protective clothing/eye protection/face protection/hearing protection. P314 - Get medical advice/attention if you feel unwell. P405 - Store locked up. P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation. Labelling according to: exemption for inner packaging where the contents do not exceed 10ml
Hazardous Ingredients
Olmesartan medoxomil
2.3 Other hazards
Contains no PBT and/or vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %
